Literature DB >> 7925269

Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA.

C Barlow1, B Meister, M Lardelli, U Lendahl, B Vennström.   

Abstract

The v-erbA oncogene consists of an avian retroviral gag gene fused to a mutated thyroid hormone receptor. To define better its role as an oncogene in mammals and its ability to function as a dominant negative transcription factor, transgenic mice expressing v-erbA ubiquitously were generated. The effects of v-erbA are pleiotropic, tissue-specific and dose dependent. Mice have breeding disorders, abnormal behavior, reduced adipose tissue, hypothyroidism with inappropriate TSH response, and enlarged seminal vesicles. This provides an animal model consistent with the proposal that v-ErbA functions as a dominant negative receptor by transcriptional interference or squelching of normal receptors or associated proteins. Finally, male animals develop hepatocellular carcinoma, demonstrating that v-erbA can promote neoplasia in mammals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7925269      PMCID: PMC395351          DOI: 10.1002/j.1460-2075.1994.tb06744.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  42 in total

1.  v-erbA cooperates with sarcoma oncogenes in leukemic cell transformation.

Authors:  P Kahn; L Frykberg; C Brady; I Stanley; H Beug; B Vennström; T Graf
Journal:  Cell       Date:  1986-05-09       Impact factor: 41.582

2.  A human beta-actin expression vector system directs high-level accumulation of antisense transcripts.

Authors:  P Gunning; J Leavitt; G Muscat; S Y Ng; L Kedes
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  Familial syndrome combining deaf-mutism, stuppled epiphyses, goiter and abnormally high PBI: possible target organ refractoriness to thyroid hormone.

Authors:  S Refetoff; L T DeWind; L J DeGroot
Journal:  J Clin Endocrinol Metab       Date:  1967-02       Impact factor: 5.958

5.  Defective v-erbB genes can be complemented by v-erbA in erythroblast and fibroblast transformation.

Authors:  M Jansson; H Beug; C Gray; T Graf; B Vennström
Journal:  Oncogene       Date:  1987-05       Impact factor: 9.867

6.  Expression of the v-erbA oncogene in chicken embryo fibroblasts stimulates their proliferation in vitro and enhances tumor growth in vivo.

Authors:  O Gandrillon; P Jurdic; M Benchaibi; J H Xiao; J Ghysdael; J Samarut
Journal:  Cell       Date:  1987-06-05       Impact factor: 41.582

7.  The c-erb-A protein is a high-affinity receptor for thyroid hormone.

Authors:  J Sap; A Muñoz; K Damm; Y Goldberg; J Ghysdael; A Leutz; H Beug; B Vennström
Journal:  Nature       Date:  1986 Dec 18-31       Impact factor: 49.962

8.  The c-erb-A gene encodes a thyroid hormone receptor.

Authors:  C Weinberger; C C Thompson; E S Ong; R Lebo; D J Gruol; R M Evans
Journal:  Nature       Date:  1986 Dec 18-31       Impact factor: 49.962

9.  Transforming capacities of avian erythroblastosis virus mutants deleted in the erbA or erbB oncogenes.

Authors:  L Frykberg; S Palmieri; H Beug; T Graf; M J Hayman; B Vennström
Journal:  Cell       Date:  1983-01       Impact factor: 41.582

10.  Functional antagonism between the estrogen receptor and Fos in the regulation of c-fos protooncogene transcription.

Authors:  C Ambrosino; L Cicatiello; G Cobellis; R Addeo; V Sica; F Bresciani; A Weisz
Journal:  Mol Endocrinol       Date:  1993-11
View more
  25 in total

Review 1.  Thyroid hormone receptors and cancer.

Authors:  Won Gu Kim; Sheue-yann Cheng
Journal:  Biochim Biophys Acta       Date:  2012-04-06

2.  Transgenic mice bearing a human mutant thyroid hormone beta 1 receptor manifest thyroid function anomalies, weight reduction, and hyperactivity.

Authors:  R Wong; V V Vasilyev; Y T Ting; D I Kutler; M C Willingham; B D Weintraub; S Cheng
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

3.  Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs.

Authors:  I H Chan; M L Privalsky
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

4.  Thyroid hormone receptor mutations found in renal clear cell carcinomas alter corepressor release and reveal helix 12 as key determinant of corepressor specificity.

Authors:  Meghan D Rosen; Martin L Privalsky
Journal:  Mol Endocrinol       Date:  2009-04-30

5.  Thyroid hormone protects hepatocytes from HBx-induced carcinogenesis by enhancing mitochondrial turnover.

Authors:  H-C Chi; S-L Chen; S-L Lin; C-Y Tsai; W-Y Chuang; Y-H Lin; Y-H Huang; M-M Tsai; C-T Yeh; K-H Lin
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

6.  The effect of oncoprotein v-erbA on thyroid hormone-regulated genes in hepatocytes and their potential role in hepatocellular carcinoma.

Authors:  Tereza Ventura-Holman; Abulkhair Mamoon; Maria C Subauste; Jose S Subauste
Journal:  Mol Biol Rep       Date:  2010-06-23       Impact factor: 2.316

Review 7.  Germline and somatic thyroid hormone receptor mutations in man.

Authors:  P M Yen; S Y Cheng
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

8.  Thyroid hormone suppresses hepatocarcinogenesis via DAPK2 and SQSTM1-dependent selective autophagy.

Authors:  Hsiang-Cheng Chi; Shen-Liang Chen; Chung-Ying Tsai; Wen-Yu Chuang; Ya-Hui Huang; Ming-Ming Tsai; Sheng-Ming Wu; Cheng-Pu Sun; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Autophagy       Date:  2016-09-21       Impact factor: 16.016

9.  Novel oncogenic actions of TRbeta mutants in tumorigenesis.

Authors:  Celine J Guigon; Sheue-yann Cheng
Journal:  IUBMB Life       Date:  2009-05       Impact factor: 3.885

10.  Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire.

Authors:  I H Chan; M L Privalsky
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.